Teplizumab is a medication used for the treatment of type 1 diabetes. It is a monoclonal antibody that targets specific immune cells that are involved in the destruction of insulin-producing beta cells in the pancreas. By targeting these immune cells, teplizumab can help to preserve or even restore insulin production, which can improve blood sugar control in people with type 1 diabetes.
Teplizumab is given as an infusion into a vein, typically over a period of 14 days. The medication is typically used in people who have been recently diagnosed with type 1 diabetes, as studies have shown that early treatment may be more effective in preserving insulin production and delaying disease progression.
Teplizumab is still considered an investigational drug and is not currently approved for widespread use in the general population. It is currently being studied in clinical trials to further evaluate its safety and efficacy, and may be used under certain circumstances through an Expanded Access Program.
It’s important to note that teplizumab is not a cure for type 1 diabetes and does not eliminate the need for insulin therapy. However, it may offer a promising new treatment option for people with this chronic condition. If you have been diagnosed with type 1 diabetes and are interested in teplizumab as a potential treatment option, it’s important to discuss your options with your healthcare provider to determine if it may be appropriate for you.
